J Korean Med Sci.  2024 Jul;39(28):e224. 10.3346/jkms.2024.39.e224.

Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients

• Jang HM
• Bae S
• Jung J
• Cho H
• Yoon DH
• Kim SH

• KMID: 2558247
• DOI: http://doi.org/10.3346/jkms.2024.39.e224

Abstract

The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1–2 years after transplant (median, 11 months; interquartile range, 9–14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], P = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT.

Keyword

Measles; Immunity; Antibody; Seropositivity; Autologous Stem Cell Transplant; Korea

Reference

1. Han SB, Park SH, Yi Y, Ji SK, Jang SH, Park MH, et al. Measles seroprevalence among healthcare workers in South Korea during the post-elimination period. Hum Vaccin Immunother. 2021; 17(8):2517–2521. PMID: 33689571.

2. Shirts BH, Welch RJ, Couturier MR. Seropositivity rates for measles, mumps, and rubella IgG and costs associated with testing and revaccination. Clin Vaccine Immunol. 2013; 20(3):443–445. PMID: 23345583.

3. Friedrich N, Poethko-Müller C, Kuhnert R, Matysiak-Klose D, Koch J, Wichmann O, et al. Seroprevalence of measles-, mumps-, and rubella-specific antibodies in the German adult population - cross-sectional analysis of the German health interview and examination survey for adults (DEGS1). Lancet Reg Health Eur. 2021; 7:100128. PMID: 34557838.

4. Lee YC, Lee YH, Lu CW, Cheng SY, Yang KC, Huang KC. Measles immunity gaps in an era of high vaccination coverage: a serology study from Taiwan. Travel Med Infect Dis. 2020; 36:101804. PMID: 32569810.

5. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. Epidemiol Infect. 2014; 142(1):12–19. PMID: 23574767.

6. Kang JH, Yoo JH. The measles strikes back. J Korean Med Sci. 2019; 34(6):e59. PMID: 30787684.

7. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143–1238. PMID: 19747629.

8. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44(8):521–526. https://pubmed.ncbi.nlm.nih.gov/33689571 . PMID: 19861986.

9. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):e44–100. PMID: 24311479.

10. Kamboj M, Shah MK. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am. 2019; 33(2):593–609. PMID: 31005140.

11. Miller P, Patel SR, Skinner R, Dignan F, Richter A, Jeffery K, et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children's Cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). J Infect. 2023; 86(1):1–8. PMID: 36400155.

12. Lee DG. Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea. Infect Chemother. 2013; 45(3):272–282. PMID: 24396628.

13. Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989; 159(4):610–615. PMID: 2647859.

14. Garcia Garrido HM, van Aalst M, Schinkel J, Koen G, Defoer JM, Hazenberg MD, et al. Early loss of immunity against measles following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2019; 94(10):E270–E272. PMID: 31342532.

15. European Centre for Disease Prevention and Control. Measles. Updated 2023. Accessed May 15, 2024. https://www.ecdc.europa.eu/sites/default/files/documents/MEAS_AER_2023_Report.pdf .

16. Pauksen K, Duraj V, Ljungman P, Sjölin J, Oberg G, Lönnerholm G, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992; 9(6):427–432. PMID: 1628126.

17. Arribas M, Ahmann GJ, Buckner Petty S, Braggio E, Theel ES, Fonseca R. Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients. Am J Hematol. 2022; 97(2):E69–E72. PMID: 34822201.

18. Kawamura K, Wada H, Nakasone H, Akahoshi Y, Kawamura S, Takeshita J, et al. Immunity and vaccination against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplant recipients. Transplant Cell Ther. 2021; 27(5):436.e1–436.e8.

19. Robin C, Mariaggi AA, Redjoul R, Leclerc M, Beckerich F, Cabanne L, et al. Long-term immunity to measles after allogeneic hematopoietic cell transplantation: factors associated with seroprotection before revaccination. Biol Blood Marrow Transplant. 2020; 26(5):985–991. PMID: 32045654.